By contrast, blocking DKK1 did not affect inflammation but led to cartilage and bone formation in inflamed joints. This report is the first to suggest a cellular and molecular mechanism underlying ...

Shin Dong-yeop, a professor of hematologic oncology at Seoul National University Hospital, recently won the Senior Researcher ...

Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET "The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can ...

In MSS colorectal cancer, sirexatamab's combo therapy showed a 32% higher ORR, 3.5-month longer PFS in high DKK1 patients vs. control. Patients without prior anti-VEGF therapy saw a 22% higher ORR ...

In the updated data announced today, Patients with high DKK1 levels, either at the upper quartile or above the median, treated in the sirexatamab Experimental Arm had significantly improved ORR ...